Discover The Desonate® Difference
Important Safety Information:
Desonate Gel is indicated for the treatment of mild to moderate atopic dermatitis in patients aged
3 months and older.
As with other corticosteroids, therapy should be discontinued when control is achieved. Unless directed by a physician, the treated skin area should not be bandaged so as to be occlusive. Systemic absorption of topical corticosteroids, including Desonate Gel, has produced HPA axis suppression, for which pediatric patients are more susceptible.
In clinical trials, the most frequent adverse events included headache (2%), application site burning (1%), rash (1%), and application site itching (<1%). The safety of Desonate Gel has not been established beyond 4 weeks of use.
Desonate Gel is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Desonate Gel is for topical use only. Desonate Gel is not for ophthalmic, oral, or intravaginal use.
Desonate Gel is not indicated for the treatment of diaper dermatitis.
Please see full prescribing information for Desonate.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-888-INFO-FDA.
References
- Trookman NS, Rizer RL, Ford RO, Gotz V. The stratum corneum and atopic dermatitis: moisturizing advantages of a novel desonide hydrogel treatment. Poster presented at: 66th Annual American Academy of Dermatology Meeting; February 1-5, 2008; San Antonio, TX. Poster 613.
- Yentzer BA, Fountain JM, Clark AR, et al. Vehicle preference in patients with atopic dermatitis. Poster presented at: 32nd Hawaii Dermatology Seminar; March 1-7, 2008; Waikoloa, HI.
- Desonate Gel [package insert]. Carlsbad, CA: SkinMedica Inc; 2007.
- Hebert AA, Cook-Bolden FE, Basu S, et al. Safety and efficacy of desonide hydrogel 0.05% in pediatric subjects with atopic dermatitis. J Drugs Dermatol. 2007;6(2):175-181.
Important Safety Information:
Desonate Gel is indicated for the treatment of mild to moderate atopic dermatitis in patients aged
3 months and older.
As with other corticosteroids, therapy should be discontinued when control is achieved. Unless directed by a physician, the treated skin area should not be bandaged so as to be occlusive. Systemic absorption of topical corticosteroids, including Desonate Gel, has produced HPA axis suppression, for which pediatric patients are more susceptible.
In clinical trials, the most frequent adverse events included headache (2%), application site burning (1%), rash (1%), and application site itching (<1%). The safety of Desonate Gel has not been established beyond 4 weeks of use.
Desonate Gel is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Desonate Gel is for topical use only. Desonate Gel is not for ophthalmic, oral, or intravaginal use.
Desonate Gel is not indicated for the treatment of diaper dermatitis.
Please see full prescribing information for Desonate.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-888-INFO-FDA.
References
- Trookman NS, Rizer RL, Ford RO, Gotz V. The stratum corneum and atopic dermatitis: moisturizing advantages of a novel desonide hydrogel treatment. Poster presented at: 66th Annual American Academy of Dermatology Meeting; February 1-5, 2008; San Antonio, TX. Poster 613.
- Yentzer BA, Fountain JM, Clark AR, et al. Vehicle preference in patients with atopic dermatitis. Poster presented at: 32nd Hawaii Dermatology Seminar; March 1-7, 2008; Waikoloa, HI.
- Desonate Gel [package insert]. Carlsbad, CA: SkinMedica Inc; 2007.
- Hebert AA, Cook-Bolden FE, Basu S, et al. Safety and efficacy of desonide hydrogel 0.05% in pediatric subjects with atopic dermatitis. J Drugs Dermatol. 2007;6(2):175-181.